This video is entirely AI generated and does not replicate any original material. It should not be considered a substitute for authentic sources. For complete context and techniques, viewers are encouraged to refer to the original content.
Based on findings from:
-
Vara Receives World-First CE Certification for Autonomous AI in Breast Cancer Screening
-
Merck and Moderna Announce Phase 3 INTerpath-001 Trial of Intismeran Autogene Plus KEYTRUDA® Met Endpoints of Recurrence-Free Survival (RFS) and Distant Metastasis-Free Survival (DMFS) in Patients With Completely Resected Stage IIB-IV Melanoma
-
Clinical decision support in hematological malignancies using a case-grounded AI agent
Julian Zoller, et al.. Nature Medicine, 2026.
DOI: 10.1038/s41591-026-04494-4
Weekly News Brief: August 31–September 4, 2026
To catch up on all of the news from this past week, listen to our weekly news brief for the week of August 31–September 4, 2026.
This week’s brief covers E.U. CE certification for an autonomous AI tool for breast cancer screening, an individualized neoantigen therapy designed with machine learning improved recurrence-free survival in resected melanoma, and a case-grounded AI agent matched board decisions for hematologic malignancies.
To learn more about Vara AI, read "CE Certification Granted to Autonomous AI Triage System for Breast Cancer Screening ," or see the press release.
For more information on intismeran autogene, read "Machine Learning–Designed Individualized Neoantigen Therapy Improves Recurrence-Free Survival in Resected Melanoma," or see the press release.
To learn more about HemaGuide, read "LLM Agent Shows Concordance With Tumor Board Decisions in Hematologic Malignancies," or see the source report in Nature Medicine.
Disclaimer: This newscast was generated with the assistance of AI tools and avatars. All content is reviewed and approved by the editorial staff of ASCO AI in Oncology. Contact us with any questions.
The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. The mention of any company, product, service, or therapy should not be construed as an endorsement of any kind. Conexiant and ASCO assume no responsibility for any injury or damage to persons or property arising out of or related to any use of material contained in this publication or to any errors or omissions.